Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results , with sales up 17.2% year on year to $794 ...

the cross-claim filed by United Therapeutics (UTHR) that sought to challenge Liquidia’s amendment to its New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder, which added ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.

United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period last year ...

Revenue: US$794.4m (up 17% from 1Q 2024). Net income: US$322.2m (up 5.1% from 1Q 2024). Profit margin: 41% (down from 45% in 1Q 2024). The decrease in margin was driven by higher expenses. EPS: US ...

CEO Martine Rothblatt highlighted that United Therapeutics achieved record revenue for the quarter, marking the ninth such achievement in the past 12 quarters. She emphasized the strong ...

Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today. All participants on the ...

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported first-quarter profit of $322.2 million. On a per-share basis, the Silver Spring ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District ...